Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SNTI | 15-12G | neutral | 2/10 | Senti Biosciences, Inc. filed Form 15-12G to terminate its SEC registration following a holding company reorganization o | May 8, 2026 |
| CLDWW | 8-K | neutral | 4/10 | Calidi Biotherapeutics issued a warrant to an accredited investor to purchase up to 17,391,304 shares at $0.23 per share | May 8, 2026 |
| PHVS | 424B5 | neutral | 4/10 | Pharvaris filed a prospectus supplement for an underwritten public offering of 3,874,664 ordinary shares at $29.68 per s | May 8, 2026 |
| NKTR | 8-K | bearish | 5/10 | Nektar Therapeutics entered into an at-the-market equity distribution agreement to sell up to $150 million of common sto | May 8, 2026 |
| TRAW | S-3 | bearish | 8/10 | Traws Pharma filed an S-3 registration statement to register 35,897,514 shares for resale by selling stockholders from a | May 8, 2026 |
| RMTI | 8-K | bearish | 7/10 | Rockwell Medical received a Nasdaq delisting notice on May 8, 2026 for failing to meet the $1.00 minimum bid price requi | May 8, 2026 |
| ICCC | 8-K | bullish | 4/10 | ImmuCell and Norbrook signed a Settlement Deed resolving claims from a 2019 agreement; Norbrook pays ImmuCell $2M. The s | May 8, 2026 |
| RXRX | CLUSTER | neutral | 2/10 | Two directors sold a total of $240K in open-market stock following the Q1 earnings release, but this represents only 0.0 | May 8, 2026 |
| RAPP | 144 | neutral | 3/10 | Third Rock Ventures V, L.P., a 10% stockholder, filed Form 144 to sell 5,018 shares of Rapport Therapeutics (RAPP) worth | May 8, 2026 |
| ODTX | 424B4 | mixed | 6/10 | Odyssey Therapeutics priced its IPO at $18.00 per share, raising $279.0 million (15.5M shares) plus a concurrent $25.0 m | May 8, 2026 |
| CSCIF | 6-K | neutral | 2/10 | COSCIENS Biopharma filed a 6-K announcing its Annual General and Special Meeting of shareholders, to be held virtually o | May 8, 2026 |
| TRAX | S-1 | neutral | 2/10 | First Tracks Biotherapeutics filed an S-1 registration statement for the resale of up to 10,497,054 shares of common sto | May 8, 2026 |
| INKT | PRESS-RELEASE | neutral | 1/10 | MiNK Therapeutics announced it will report its Q1 2026 results on May 15, 2026. | May 8, 2026 |
| INBP | 8-K | bearish | 7/10 | Integrated BioPharma reported Q3 FY2026 (quarter ended March 31, 2026) results with revenue of $10.1M, down 27.3% YoY fr | May 8, 2026 |
| VTGN | 8-K | neutral | 3/10 | Vistagen announced the completion of the last patient visit in the randomized portion of its PALISADE-4 Phase 3 trial ev | May 8, 2026 |
| ARTV | 8-K | bearish | 7/10 | Artiva Biotherapeutics priced a $300M underwritten public offering of 23.9M shares and pre-funded warrants for 2.2M shar | May 8, 2026 |
| LGVN | 8-K | bearish | 7/10 | Longeveron disclosed that the FDA rejected the primary endpoint (RVEF) of its Phase 2b ELPIS II trial for HLHS, and the | May 8, 2026 |
| ADTX | 8-K | bearish | 8/10 | Aditxt received a Nasdaq Staff Determination on May 6, 2026, that its securities will be delisted from The Nasdaq Capita | May 8, 2026 |
| ENTX | S-3 | neutral | 3/10 | Entera Bio filed an S-3 to register 19.6M ordinary shares for resale by BVF entities, issued in a $10M private placement | May 8, 2026 |
| GNMSF | 6-K | neutral | 2/10 | Orbis Investment Management Limited disclosed a 5.08% passive stake in Genmab A/S, up from the previous 4.85% holding. T | May 8, 2026 |
| RGC | 6-K | bearish | 7/10 | Regencell Bioscience reported H1 FY2026 results with net loss widening 187% to $5.32M, driven by elevated legal and shar | May 8, 2026 |
| IBIO | 8-K | neutral | 2/10 | iBio appointed Dr. Elizabeth Stoner to its Board of Directors, replacing Evert Schimmelpennink who resigned. Dr. Stoner | May 8, 2026 |
| VTVT | PRESS-RELEASE | neutral | 2/10 | vTv Therapeutics granted 39,500 stock options to two non-executive employees as inducement awards. This is a routine com | May 8, 2026 |
| BKHAU | 8-K | neutral | 2/10 | Black Hawk Acquisition Corp., a SPAC, issued a convertible promissory note to its sponsor for up to $300,000 at 10% inte | May 8, 2026 |
| VRDN | 424B5 | bearish | 6/10 | Viridian Therapeutics is raising $225M via 1.75% convertible notes due 2032 (plus $25M over-allotment) and concurrently | May 8, 2026 |
| TOMZ | 8-K | mixed | 7/10 | TOMI reported Q1 2026 revenue of $1.65M (up 5% YoY but missed the $1.7M consensus) and EPS of -$0.04 (in line). More imp | May 8, 2026 |
| ENTX | 8-K | neutral | 5/10 | Entera Bio reported Q1 2026 net loss of $3.5M ($-0.07/share), beating the $-0.08 consensus by 12.5%. The pre-revenue bio | May 8, 2026 |
| MBX | CLUSTER | neutral | 2/10 | Two top executives (CEO and CMO) sold a total of $25K in open-market sales on May 6, 2026, one day after Q1 earnings bea | May 8, 2026 |
| SIGA | DEFA14A | neutral | 2/10 | SIGA Technologies filed a DEFA14A supplement to its 2026 proxy statement, correcting errors in Proposal 4 regarding the | May 8, 2026 |
| BFRI | PRESS-RELEASE | neutral | 1/10 | Biofrontera Inc. announced it will report its Q1 2026 results on May 14, 2026. | May 8, 2026 |